phenelzine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2123 51-71-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phenelzine
  • 1-hydrazino-2-phenylethane
  • 2-phenylethylhydrazine
  • phenalzine
  • phenethylhydrazine
  • phenelzine sulfate
One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.
  • Molecular weight: 136.20
  • Formula: C8H12N2
  • CLOGP: 1.03
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 2
  • TPSA: 38.05
  • ALOGS: -1.09
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAP4K3,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 54
kinase-selectivity-class AKT2,AKT3,AXL,BRAF,CAMK2D,CDK7,DDR1,EIF2AK3,EPHB4,FLT3,GRK2,INSR,MAP4K1,MAP4K3,MAPK12,MAPK7,MELK,NUAK1,PAK4,PDK4,PRKACA,PRKCD,PRKG1,ROCK1,SIK2,SIK3,STK33,TEK,ULK2 29
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
June 9, 1961 FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serotonin syndrome 130.24 35.76 38 1080 37849 90589480
Drug interaction 94.16 35.76 52 1066 276401 90350928
Product complaint 48.30 35.76 14 1104 13486 90613843
Hypertensive crisis 44.49 35.76 14 1104 17770 90609559
Food interaction 35.79 35.76 7 1111 1257 90626072

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 43.24 41.53 42 411 630155 41990727

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serotonin syndrome 141.86 31.87 44 1200 59109 110528946
Drug interaction 98.63 31.87 64 1180 500119 110087936
Hypertensive crisis 33.68 31.87 12 1232 24360 110563695
Food interaction 32.71 31.87 7 1237 2145 110585910

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AF03 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Monoamine oxidase inhibitors, non-selective
FDA MoA N0000000184 Monoamine Oxidase Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D008996 Monoamine Oxidase Inhibitors
MeSH PA D011619 Psychotropic Drugs
FDA EPC N0000175744 Monoamine Oxidase Inhibitor
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

N06AF Monoamine oxidase inhibitors, non-selective 5 drugs
iproclozideiproniazidisocarboxazidnialamidetranylcypromine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Bulimia nervosa off-label use 78004001
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Feeling agitated contraindication 24199005
Orthostatic hypotension contraindication 28651003
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Anxiety contraindication 48694002
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Schizophrenia contraindication 58214004 DOID:5419
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Syncope contraindication 271594007
Pheochromocytoma contraindication 302835009
Myelogram contraindication 367401004
Disorder of coronary artery contraindication 414024009
Hypertensive Emergencies contraindication
Severe Headache Disorder contraindication
Frequent Headache Disorder contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.59 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Amine oxidase [flavin-containing] A Enzyme INHIBITOR IC50 6.84 DRUG MATRIX CHEMBL
Amine oxidase [flavin-containing] B Enzyme INHIBITOR Ki 7.82 IUPHAR CHEMBL
Cytochrome P450 2D6 Enzyme IC50 6 DRUG MATRIX
Cytochrome P450 2C8 Enzyme INHIBITOR Ki 5.14 IUPHAR
Cytochrome P450 2C9 Enzyme IC50 5.40 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 6.10 DRUG MATRIX
Membrane primary amine oxidase Enzyme IC50 7.70 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 4.85 CHEMBL
Lysine-specific histone demethylase 1A Enzyme Ki 4.75 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 5.70 DRUG MATRIX
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.12 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.08 PDSP
Amine oxidase [flavin-containing] B Enzyme IC50 7.12 CHEMBL
Amine oxidase [flavin-containing] A Enzyme IC50 7.52 CHEMBL

External reference:

IDSource
4019886 VUID
N0000147971 NUI
D00505 KEGG_DRUG
156-51-4 SECONDARY_CAS_RN
4018632 VANDF
4019886 VANDF
C0031392 UMLSCUI
CHEBI:8060 CHEBI
CHEMBL1089 ChEMBL_ID
3675 PUBCHEM_CID
DB00780 DRUGBANK_ID
CHEMBL1200895 ChEMBL_ID
D010624 MESH_DESCRIPTOR_UI
919 INN_ID
7266 IUPHAR_LIGAND_ID
O408N561GF UNII
8123 RXNORM
178818 MMSL
5269 MMSL
d00883 MMSL
001495 NDDF
004596 NDDF
21614004 SNOMEDCT_US
387528000 SNOMEDCT_US
9500005 SNOMEDCT_US
O408N561GF INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nardil HUMAN PRESCRIPTION DRUG LABEL 1 0071-0350 TABLET, FILM COATED 15 mg ORAL NDA 19 sections
Phenelzine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 40032-360 TABLET 15 mg ORAL ANDA 13 sections
Phenelzine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 43386-360 TABLET 15 mg ORAL ANDA 15 sections
phenelzine sulfate HUMAN PRESCRIPTION DRUG LABEL 1 59762-0119 TABLET, FILM COATED 15 mg ORAL NDA AUTHORIZED GENERIC 20 sections